Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Trisura Group Ltd T.TSU

Alternate Symbol(s):  TRRSF

Trisura Group Ltd. is a specialty insurance provider. The Company is engaged in operating in surety, risk solutions, corporate insurance, and fronting business lines of the market. It has investments in subsidiaries through which it conducts insurance and reinsurance operations. Those operations are primarily in Canada (Trisura Canada) and the United States (Trisura US). Its segments include... see more

TSX:TSU - Post Discussion

View:
Post by retiredcf on Nov 10, 2024 9:05am

RBC 2

Their upside scenario target is $54.00. Once again, huge cut and paste problems. GLTA

November 8, 2024

Outperform

TSX: TSU; CAD 43.42

Price Target CAD 49.00 ↓ 52.00

Trisura Group Ltd.
Q3 in line overall, mixed growth trends by segment

Our view

Overall Q3 results were relatively in line with Trisura Specialty (formerly the Canada unit) performing well again across the board. We viewed the U.S. Programs unit as more mixed as growth was dragged down by program exits and an operational fronting ratio that was a bit higher than 1H24 levels. U.S. surety premiums were notable in Q3. We think that Trisura is positioned for growth and solid profitability. Book value grew nicely on a sequential basis and its capital ratios (debt/cap. and premium/capital ratio) improved vs. recent quarters.

Key points:

Estimates & Price Target:

Our 2024 EPS estimate goes to $2.63 (from $2.65) on modest Q4 assumption tweaks. We are revising our 2025 EPS forecast to $2.95 (from $3.05) on reduced investment income and premium growth assumptions. We are introducing a 2026 EPS estimate of $3.30. We are revising our price target to $49 (from $52) which is now based on 2.7x our ending 2025 book value per share estimate (previously 3.0x). Our price target reflects a reduced multiple on our slightly lower EPS trajectory

Q3 results: Trisura reported Q3/24 operating EPS of $0.68 vs. $0.67 in Q3/23, which matched our $0.68 estimate and was $0.01/share ahead of the $0.67 consensus expectation. Both operating segments were in line with our estimates on an operating basis.

Key Takeaways:

Operating income for the Trisura Specialty segment totaled $21.7 mm vs. $21.1 mm. The combined ratio for Trisura Specialty was 85.6% vs. 75.0%, which was close to our 85.0% assumption. Gross written premiums at Trisura Specialty grew +15.2% y/y to $278.4 mm vs. $241.7 mm (RBC estimate was +20.0%) while net written premiums rose +19.2% y/y to $158.5 mm (RBC estimate was +16.7%). Overall operating income for U.S. Programs totaled $12.7 mm vs. $11.4 million last year. The U.S. fronting operational ratio (ex items) was 87.4% and the reported operating fronting operational ratio was 95.0%. The company guided to a low 80s operating fronting ratio for this unit in the near term. Gross written premiums declined 7.4% y/y to $489.3 mm vs. $528.2 mm last year (RBC estimate was -1.0%) as there was a drag from several nonrenewed programs that didn’t meet their risk appetite (ex that impact GWP would have been up around 20%). Net written premiums were $47.2 mm vs. $40.2 mm.

Positives:

1) Net written premium growth trends strong across both segments; 2) Sequential book value growth was healthy; and 3) Trisura  Specialty combined ratio again in the mid 80s.

Negatives:

1) U.S. Programs operational fronting ratio ticked up; 2)Gross written premium growth decelerated from recent quarters; and 3) Investment income didn't show sequential growth.


 



Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities